Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1989 Mar;59(3):327–334. doi: 10.1038/bjc.1989.65

Enhanced therapeutic efficacy of 5'deoxy-5-fluorouridine in 5-fluorouracil resistant head and neck tumours in relation to 5-fluorouracil metabolising enzymes.

G J Peters 1, B J Braakhuis 1, E A de Bruijn 1, E J Laurensse 1, M van Walsum 1, H M Pinedo 1
PMCID: PMC2247094  PMID: 2522792

Abstract

Four human head and neck xenograft (HNX) tumour lines grown in nude mice and two murine colon carcinomas (Colon 26 and 38) were tested for their sensitivity to 5-fluorouracil (5-FU) and its prodrug 5'deoxy-5-fluorouridine (Doxifluridine, 5'd-FUR). 5-FU sensitivity at the maximum tolerated dose (MTD) showed the following pattern; HNX-DU less than HNX-KE = HNX-E = HNX-G less than Colon 26 much less than Colon 38. The sensitivity pattern to 5'd-FUR was: HNX-DU less than HNX-G less than HNX-E less than HNX-KE less than Colon 38 less than Colon 26. For HNX-KE, HNX-E and Colon 26 an increase in therapeutic efficacy was observed with 5'd-FUR as compared to 5-FU; Colon 38 was as sensitive to 5'd-FUR as to 5-FU. Plasma pharmacokinetics of 5'd-FUR and 5-FU were comparable in normal and nude mice. Metabolism of 5-FU and 5'd-FUR was studied in the tumours. Conversion of 5'd-FUR to 5-FU was highest in Colon 26 and 15-20 times lower in HNX-DU, HNX-KE and Colon 38. The Km for 5'd-FUR in all tumours was 1-2 mM. Further anabolism of 5-FU to fluorouridine (FUR) was 5-10 times higher than that of 5-FU to FUR in HNX tumours and 3 times in the colon tumours. 5-FU conversion to FUMP via FUR had the following pattern: Colon 26 much greater than HNX-DU greater than HNX-G greater than HNX-E greater than HNX-KE much greater than Colon 38; of 5-FU to FdUMP via FUdR: Colon 26 greater than HNX-DU = HNX-KE greater than HNX-E greater than HNX-G = Colon 38; and that of 5-FU to FUMP catalysed by orotate phosphoribosyl transferase (OPRT); Colon 26 greater than or equal to Colon 38 greater than HNX-KE greater than HNX-E = HNX-DU = HNX-G. Only those tumours with a relatively high activity of OPRT were sensitive to 5'd-FUR. Colon 26, which has a very high rate of pyrimidine nucleoside phosphorylase, showed a relatively high increase in the therapeutic efficacy. It is concluded that a low rate of pyrimidine nucleoside phosphorylase is enough to convert 5'd-FUR to 5-FU; further anabolism of 5-FU catalysed by OPRT may be limiting and explain the differential sensitivity.

Full text

PDF
327

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abele R., Kaplan E., Grossenbacher R., Schmid H. J., Cavalli F. Phase II study of doxifluridine in advanced squamous cell carcinoma of the head and neck. Eur J Cancer Clin Oncol. 1984 Mar;20(3):333–336. doi: 10.1016/0277-5379(84)90078-6. [DOI] [PubMed] [Google Scholar]
  2. Alberto P., Mermillod B., Germano G., Kaplan S., Weber W., Joss R., Spati B., Martz G., Cavalli F. A randomized comparison of doxifluridine and fluorouracil in colorectal carcinoma. Eur J Cancer Clin Oncol. 1988 Mar;24(3):559–563. doi: 10.1016/s0277-5379(98)90037-2. [DOI] [PubMed] [Google Scholar]
  3. Armstrong R. D., Diasio R. B. Metabolism and biological activity of 5'-deoxy-5-fluorouridine, a novel fluoropyrimidine. Cancer Res. 1980 Sep;40(9):3333–3338. [PubMed] [Google Scholar]
  4. Armstrong R. D., Diasio R. B. Selective activation of 5'-deoxy-5-fluorouridine by tumor cells as a basis for an improved therapeutic index. Cancer Res. 1981 Dec;41(12 Pt 1):4891–4894. [PubMed] [Google Scholar]
  5. Barankiewicz J., Henderson J. F. Determination of ribose 1-phosphate in ascites tumor cells. Biochem Med. 1977 Feb;17(1):45–53. doi: 10.1016/0006-2944(77)90008-4. [DOI] [PubMed] [Google Scholar]
  6. Bollag W., Hartmann H. R. Tumor inhibitory effects of a new fluorouracil derivative: 5'-deoxy-5-fluorouridine. Eur J Cancer. 1980 Apr;16(4):427–432. doi: 10.1016/0014-2964(80)90221-2. [DOI] [PubMed] [Google Scholar]
  7. Braakhuis B. J., Leyva A., Schoevers E. J., Boerrigter G. H., Schornagel J. H., Snow G. B. Lack of effect of methotrexate on human head and neck tumours transplanted in athymic nude mice. Acta Otolaryngol. 1985 Mar-Apr;99(3-4):208–213. doi: 10.3109/00016488509108899. [DOI] [PubMed] [Google Scholar]
  8. Braakhuis B. J., Schoevers E. J., Heinerman E. C., Sneeuwloper G., Snow G. B. Chemotherapy of human head and neck cancer xenografts with three clinically active drugs: cis-platinum, bleomycin and methotrexate. Br J Cancer. 1983 Nov;48(5):711–716. doi: 10.1038/bjc.1983.254. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Braakhuis B. J., Sneeuwloper G., Snow G. B. The potential of the nude mouse xenograft model for the study of head and neck cancer. Arch Otorhinolaryngol. 1984;239(1):69–79. doi: 10.1007/BF00454264. [DOI] [PubMed] [Google Scholar]
  10. Choong Y. S., Lee S. P. The degradation of 5'-deoxy-5-fluorouridine by pyrimidine nucleoside phosphorylase in normal and cancer tissues. Clin Chim Acta. 1985 Jul 15;149(2-3):175–183. doi: 10.1016/0009-8981(85)90331-6. [DOI] [PubMed] [Google Scholar]
  11. Cory J. G., Carter G. L. Evidence that 5'-deoxy-5-fluorouridine may not be activated by the same mechanism as 5-fluorouracil. Biochem Pharmacol. 1982 Sep 1;31(17):2841–2844. doi: 10.1016/0006-2952(82)90146-0. [DOI] [PubMed] [Google Scholar]
  12. Greenberg N., Schumm D. E., Webb T. E. Uridine kinase activities and pyrimidine nucleoside phosphorylation in fluoropyrimidine-sensitive and -resistant cell lines of the Novikoff hepatoma. Biochem J. 1977 May 15;164(2):379–387. doi: 10.1042/bj1640379. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Hartmann H. R., Matter A. Antiproliferative action of a novel fluorinated uridine analog, 5'-deoxy-5-fluorouridine, measured in vitro and in vivo on four different murine tumor lines. Cancer Res. 1982 Jun;42(6):2412–2415. [PubMed] [Google Scholar]
  14. Hurteloup P., Armand J. P., Cappelaere P., Metz R., Kerbrat P., Keiling R., Fumoleau P., Fargeot P., Schraub S., Bastit P. Phase II clinical evaluation of doxifluridine. Cancer Treat Rep. 1986 Jun;70(6):731–737. [PubMed] [Google Scholar]
  15. Ishitsuka H., Miwa M., Takemoto K., Fukuoka K., Itoga A., Maruyama H. B. Role of uridine phosphorylase for antitumor activity of 5'-deoxy-5-fluorouridine. Gan. 1980 Feb;71(1):112–123. [PubMed] [Google Scholar]
  16. Laurensse E. J., Pinedo H. M., Peters G. J. A sensitive non-radioactive assay for pyrimidine nucleoside phosphorylase using reversed-phase high performance liquid chromatography. Clin Chim Acta. 1988 Nov;178(1):71–78. doi: 10.1016/0009-8981(88)90270-7. [DOI] [PubMed] [Google Scholar]
  17. Leyva A., Kraal I., Lankelma J., Delemarre J. F., Pinedo H. M. High uridine phosphorylase activity in human melanoma tumor. Anticancer Res. 1983 Jul-Aug;3(4):227–231. [PubMed] [Google Scholar]
  18. Miwa M., Nakamura J., Ishitsuka H. A simple and convenient assay method for phosphorolysis of 5'-deoxy-5-fluorouridine. Gan. 1981 Dec;72(6):965–968. [PubMed] [Google Scholar]
  19. Peters G. J., Laurensse E. J., Leyva A., Pinedo H. M. Tissue homogenization using a micro-dismembrator for the measurement of enzyme activities. Clin Chim Acta. 1986 Jul 30;158(2):193–198. doi: 10.1016/0009-8981(86)90236-6. [DOI] [PubMed] [Google Scholar]
  20. Peters G. J., Laurensse E., Lankelma J., Leyva A., Pinedo H. M. Separation of several 5-fluorouracil metabolites in various melanoma cell lines. Evidence for the synthesis of 5-fluorouracil-nucleotide sugars. Eur J Cancer Clin Oncol. 1984 Nov;20(11):1425–1431. doi: 10.1016/0277-5379(84)90063-4. [DOI] [PubMed] [Google Scholar]
  21. Peters G. J., Laurensse E., Leyva A., Lankelma J., Pinedo H. M. Sensitivity of human, murine, and rat cells to 5-fluorouracil and 5'-deoxy-5-fluorouridine in relation to drug-metabolizing enzymes. Cancer Res. 1986 Jan;46(1):20–28. [PubMed] [Google Scholar]
  22. Peters G. J., Laurensse E., Leyva A., Pinedo H. M. Purine nucleosides as cell-specific modulators of 5-fluorouracil metabolism and cytotoxicity. Eur J Cancer Clin Oncol. 1987 Dec;23(12):1869–1881. doi: 10.1016/0277-5379(87)90053-8. [DOI] [PubMed] [Google Scholar]
  23. Peters G. J., Laurensse E., Leyva A., Pinedo H. M. The concentration of 5-phosphoribosyl 1-pyrophosphate in monolayer tumor cells and the effect of various pyrimidine antimetabolites. Int J Biochem. 1985;17(1):95–99. doi: 10.1016/0020-711x(85)90091-6. [DOI] [PubMed] [Google Scholar]
  24. Peters G. J., Van Dijk J., Nadal J. C., Van Groeningen C. J., Lankelma J., Pinedo H. M. Diurnal variation in the therapeutic efficacy of 5-fluorouracil against murine colon cancer. In Vivo. 1987 Mar-Apr;1(2):113–117. [PubMed] [Google Scholar]
  25. Pinedo H. M., Peters G. F. Fluorouracil: biochemistry and pharmacology. J Clin Oncol. 1988 Oct;6(10):1653–1664. doi: 10.1200/JCO.1988.6.10.1653. [DOI] [PubMed] [Google Scholar]
  26. Sommadossi J. P., Aubert C., Cano J. P., Gouveia J., Ribaud P., Mathé G. Kinetics and metabolism of a new fluoropyrimidine, 5'-deoxy-5-fluorouridine, in humans. Cancer Res. 1983 Feb;43(2):930–933. [PubMed] [Google Scholar]
  27. Tannock I. F., Browman G. Lack of evidence for a role of chemotherapy in the routine management of locally advanced head and neck cancer. J Clin Oncol. 1986 Jul;4(7):1121–1126. doi: 10.1200/JCO.1986.4.7.1121. [DOI] [PubMed] [Google Scholar]
  28. Wataya Y., Santi D. W. Continuous spectrophotometric assay of thymidine phosphorylase using 5-nitro-2'-deoxyuridine as substrate. Anal Biochem. 1981 Mar 15;112(1):96–98. doi: 10.1016/0003-2697(81)90265-7. [DOI] [PubMed] [Google Scholar]
  29. Winograd B., Boven E., Lobbezoo M. W., Pinedo H. M. Human tumor xenografts in the nude mouse and their value as test models in anticancer drug development (review). In Vivo. 1987 Jan-Feb;1(1):1–13. [PubMed] [Google Scholar]
  30. Woodman P. W., Sarrif A. M., Heidelberger C. Specificity of pyrimidine nucleoside phosphorylases and the phosphorolysis of 5-fluoro-2'-deoxyuridine. Cancer Res. 1980 Mar;40(3):507–511. [PubMed] [Google Scholar]
  31. de Bruijn E. A., van Oosterom A. T., Tjaden U. R., Reeuwijk H. J., Pinedo H. M. Pharmacology of 5'-deoxy-5-fluorouridine in patients with resistant ovarian cancer. Cancer Res. 1985 Nov;45(11 Pt 2):5931–5935. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES